{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:37:50Z","timestamp":1787769470413,"version":"build-2784847793"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To evaluate the outcomes after stereotactic body radiotherapy (SBRT) for locally advanced primary liver cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Patients with locally advanced liver cancer unsuitable for other loco-regional treatments were treated with SBRT with 50\u201360 Gy in 3\u201312 fractions in two consecutive prospective trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 83 patients were included, of whom 14 were excluded, leaving 69 evaluable patients with 74 treated lesions. A total of 50 patients had hepatocellular carcinoma (HCC), and 11 patients had cholangiocarcinoma (CCC). Approximately 76% had a Child-Pugh (CP) score of A, while 54% had an albumin\u2013bilirubin (ALBI) score of 1. With a median follow-up of 29 months, the median overall survival (OS) was 11 months, and the progression-free survival (PFS) was 18 months. The ALBI score was an important predictor of overall survival (HR 2.094, p = 0.001), which remained significant also in the multivariate analysis. Patients with an ALBI grade of \u22651 had an OS of 4 months versus 23 months in patients with an ALBI grade of 1 (p \u2264 0.001). The local control at 1 and 2 years was 91%. Thirteen patients developed grade \u2265 3 toxicities, of whom nine patients experienced liver toxicities. Patients with a higher ALBI score had a high risk for developing hepatic failure (OR 6.136, p = 0.006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>SBRT is a very effective treatment with low toxicity and should be considered as a local treatment option in patients with HCC and CCC. Patients with a higher ALBI grade are at risk for developing toxicities after SBRT and have a significantly lower survival rate.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1427332","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T04:10:20Z","timestamp":1727928620000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of ALBI score in patients treated with stereotactic body radiotherapy for locally advanced primary liver tumors: a pooled analysis of two prospective studies"],"prefix":"10.3389","volume":"14","author":[{"given":"Eleni","family":"Gkika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Radicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Eichhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kirste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sprave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Henrik","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Fichtner-Feigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wiehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00018-024-05236-w","article-title":"Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance","volume":"81","author":"Ashrafizadeh","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"103981","DOI":"10.1016\/j.drudis.2024.103981","article-title":"Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy","volume":"29","author":"Dai","year":"2024","journal-title":"Drug Discovery Today"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604387","article-title":"The evolving role of radiation therapy in the treatment of biliary tract cancer","volume":"10","author":"Gkika","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.653141","article-title":"Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization (HERACLES: HEpatocellular carcinoma stereotactic RAdiotherapy CLinical efficacy study)","volume":"11","author":"Brunner","year":"2021","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","article-title":"Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial)","volume":"117","author":"M\u00e9ndez Romero","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver Malignancies: Meta-analyses and a systematic review","volume":"145","author":"Lee","year":"2020","journal-title":"Radiother Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-017-1256-0","article-title":"The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy","volume":"194","author":"Gkika","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13014-017-0851-7","article-title":"Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma","volume":"12","author":"Gkika","year":"2017","journal-title":"Radiat Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-023-00358-z","article-title":"Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer","volume":"7","author":"Gkika","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00066-013-0450-y","article-title":"Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer","volume":"190","author":"Guckenberger","year":"2014","journal-title":"Strahlentherapie und Onkol: Organ der Deutschen Rontgengesellschaft \u2026 [et al]"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.06.2147","article-title":"Simultaneous integrated protection: A new concept for high-precision radiation therapy","volume":"192","author":"Brunner","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1007\/s00066-017-1099-8","article-title":"Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Stereotaktische Strahlentherapie (SBRT) beim wiederkehrenden oder oligometastatischen Pankreaskarzinom : Bewertung der Toxizit\u00e4t bei simultan integrierter Protektion (SIP) versus konventioneller SBRT","volume":"193","author":"Gkika","year":"2017","journal-title":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.07.691","article-title":"A challenge to traditional radiation oncology","volume":"60","author":"Fowler","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.03.003","article-title":"The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients","volume":"135","author":"Prayongrat","year":"2019","journal-title":"Radiother Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0011-3840(64)80003-4","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major problems in clinical surgery"},{"key":"B22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.08.015","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: meta-analysis and international stereotactic radiosurgery society practice guidelines","volume":"118","author":"Bae","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.05.002","article-title":"Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma","volume":"111","author":"Culleton","year":"2014","journal-title":"Radiother Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.04.011","article-title":"Stereotactic body radiotherapy for primary hepatocellular carcinoma","volume":"81","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.04.011","article-title":"Baseline albumin-bilirubin (ALBI) score in western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT)","volume":"101","author":"Murray","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.04.012","article-title":"The potential for midtreatment albumin-bilirubin (ALBI) score to individualize liver stereotactic body radiation therapy","volume":"111","author":"Jackson","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1427332\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T04:10:23Z","timestamp":1727928623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1427332\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":28,"alternative-id":["10.3389\/fonc.2024.1427332"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1427332","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"article-number":"1427332"}}